DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Kristeleit RS, Shapira-Frommer R, Oaknin A. et al.
Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2).
Ann Oncol 2016;
27: vi296
doi:10.1093/annonc/mdw374.03
We do not assume any responsibility for the contents of the web pages of other providers.